BioSpace News Archive

Provides Update on End of Phase Type-B Meeting with FDA

Guardant Health, Inc. reported financial results for the third quarter ended September 30, 2019.

Reports Net Revenues of $80.1 Million for the Three Months Ended September 30, 2019

NanoFlu pivotal Phase 3 clinical trial initiated October 2019 with top-line data expected in the first quarter of 2020

Accelerate Diagnostics, Inc. announced financial results for the third quarter ended September 30, 2019.

Immunic, Inc. announced financial results for the third quarter ended September 30, 2019 and highlighted recent activity.

Revenue from commercial therapies increased 368% over same quarter last year and 39% sequentially

Medifast, Inc., a leading manufacturer and distributor of clinically proven programs and healthy living products, reported results for the third quarter ended September 30, 2019.

NovaBay® Pharmaceuticals, Inc., a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, reports financial results for the three and nine months ended September 30, 2019 and provides a business update.

POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that company management will present at two upcoming investor conferences in November